ArticleScience (New York, N.Y.)2019
Targeted selection of HIV-specific antibody mutations by engineering B cell maturation.
Abstract read
In one paragraph
Article in Science (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers.
0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
126 citing papers in PubMed.
- Vaccination induces HIV broadly neutralizing antibody precursors in humans.Science (New York, N.Y.) · 2022Trial
- Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.Nature medicine · 2022Trial
- Deletions in variable region 1 of the HIV envelope accelerate V3-glycan bNAb induction in SHIV-infected rhesus macaques.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- SorLA regulates B cell receptor uptake, trafficking, and B cell-mediated immune responses in vivo.The Journal of experimental medicine · 2026Article
- Review
- Article
- Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design.Science (New York, N.Y.) · 2026Article
- mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Recent advances in HIV-1 envelope-based vaccine designs for guiding broadly neutralizing antibody response.Journal of virology · 2026Review
- Germline-targeting HIV immunogen induces cross-neutralizing antibodies in outbred macaques.Immunity · 2026Article
- Contemporary HIV-1 envelope pseudovirus panels for detecting and assessing B cell lineages with broadly neutralizing antibody potential.PLoS pathogens · 2026Article
- Germline-somatic residue synergy reshapes antibody encounter-state pathways to enhance HIV-1 recognition.bioRxiv : the preprint server for biology · 2026Article
- Ferritin nanoparticles displaying rift valley fever virus glycoprotein elicit potent dendritic cell activation in vitro.Virology journal · 2026Article
- Early clonal dominance at priming sets the trajectory for broad HIV serum neutralization.bioRxiv : the preprint server for biology · 2026Article
- Predicting viral sensitivity to antibodies using genetic sequences and antibody similarities.PLoS computational biology · 2026Article
- Rapid elicitation of neutralizing Asn332-glycan-independent antibodies to the V3-glycan epitope of HIV-1 Env in nonhuman primates.Nature immunology · 2026Article
- Computing the inducibility of broadly neutralizing antibodies under a context-dependent model of affinity maturation: applications to sequential vaccine design.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- A Mammalian Surface Display Platform to Optimize the Antigenicity of Viral Proteins for Vaccine Design.bioRxiv : the preprint server for biology · 2026Article
- Integration of Preclinical and Clinical Vaccine Safety and Immunogenicity Testing for Development of a Pediatric HIV Vaccine to Achieve Protective HIV Immunity Prior to Adolescence.Current HIV research · 2026Review
- Current Approaches for Assessments of Neutralizing, Binding, and Effector Functions of Antibodies on the Path to Antibody-Mediated Prevention Strategies for HIV-1.Current HIV research · 2026Review
66 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
35 authors.
Kevin O SaundersHuman Vaccine Institute and Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA. kevin.saunders@duke.edu barton.haynes@duke.edu alt@enders.tch.harvard.edu.ORCID 0000-0001-7399-7954
Kevin WieheHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0001-9933-9618
Ming TianHoward Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-4350-3380
Priyamvada AcharyaHuman Vaccine Institute and Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-0089-277X
Todd BradleyHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-1601-631X
S Munir AlamHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-0941-0703
Eden P GoDepartment of Chemistry, University of Kansas, Lawrence, KS 66049, USA.
Richard ScearceHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-6361-3758
Laura SutherlandHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-4119-3884
Rory HendersonHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-4301-6382
Allen L HsuGenome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, NC 27709, USA.ORCID 0000-0003-2065-3802
Mario J BorgniaGenome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, NC 27709, USA.ORCID 0000-0001-9159-1413
Haiyan ChenHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Xiaozhi LuHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Nelson R WuHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-2612-8729
Brian WattsHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Chuancang JiangHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
David EasterhoffHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Hwei-Ling ChengHoward Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Kelly McGovernHoward Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-0778-4499
Peyton WaddicorHoward Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-2003-5505
Aimee Chapdelaine-WilliamsHoward Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Amanda EatonHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-3064-2947
Jinsong ZhangHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Wes RountreeHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0001-5183-6949
Laurent VerkoczyHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Mark TomaiCorporate Research Materials Lab, 3M Company, St. Paul, MN 55144, USA.ORCID 0000-0002-6362-9151
Mark G LewisBioqual, Rockville, MD 20850, USA.ORCID 0000-0001-7852-0135
Heather R DesaireDepartment of Chemistry, University of Kansas, Lawrence, KS 66049, USA.
Robert J EdwardsHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-4446-1194
Derek W CainHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-5988-6729
Mattia BonsignoriHuman Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-2973-2101
David MontefioriHuman Vaccine Institute and Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-0856-6319
Frederick W AltHoward Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA. kevin.saunders@duke.edu barton.haynes@duke.edu alt@enders.tch.harvard.edu.ORCID 0000-0002-0583-1271
Barton F HaynesDepartment of Immunology, Duke University School of Medicine, Durham, NC 27710, USA. kevin.saunders@duke.edu barton.haynes@duke.edu alt@enders.tch.harvard.edu.ORCID 0000-0002-2847-1854
Funding
Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7MNonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodiesUM1AI144371 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2025
$190.4MVirus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7MNIEHS Cryo-EM Core FacilityZICES103326 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI BORGNIA, MARIO · 2017 to 2025
$17.0MHIV-1 vaccine-elicited antibodies target envelope glycansR01AI120801 · NIAID · DUKE UNIVERSITY · PI SAUNDERS, KEVIN O · 2015 to 2024
$7.5MMPER broadly neutralizing antibody knockin mice to study anti-HIV Bcell responsesR01AI087202 · NIAID · SAN DIEGO BIOMEDICAL RESEARCH INSTITUTE · PI VERKOCZY, LAURENT KARL · 2010 to 2022
$5.5MGenerating Native Env Glycosylation in HIV Vaccine CandidatesR01AI125093 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI DESAIRE, HEATHER R · 2016 to 2019
$2.7MHoward Hughes Medical InstituteIntramural NIH HHS ZIC ES103326NIAID NIH HHS P01 AI131251NIAID NIH HHS R01 AI087202NIAID NIH HHS R01 AI120801NIAID NIH HHS R01 AI125093NIAID NIH HHS UM1 AI100645NIAID NIH HHS UM1 AI144371
Abstract
PubMed holds no abstract for this paper.
Indexed as
Selection, GeneticAIDS VaccinesAnimalsAntibody AffinityB-Lymphocytesenv Gene Products, Human Immunodeficiency VirusEpitopesGene Knock-In TechniquesHIV-1HIV AntibodiesHumansMacacaMiceMice, Mutant StrainsMutationAIDS Vaccinesenv Gene Products, Human Immunodeficiency VirusEpitopesHIV Antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.